Long-term denosumab therapy safe for patients with breast, prostate cancer
the ONA take:
No new safety signals were identified for long-term denosumab therapy in patients with metastatic breast or prostate cancer and bone metastases, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
In the initial blinded phase 3 studies, patients with metastatic breast or prostate cancer received subcutaenous denosumab 120 mg every 4 weeks or intravenous zolendronic acid 4 mg every 4 weeks.
Denosumab was found to be superior in efficacy to zoledronic acid, and therefore patients could opt to participate in an open-label extension to receive long-term denosumab for up to an additional 2 years.
Researchers analyzed the data from the open-label extension to evaluate the safety results of extended denosumab therapy.
Results showed no new safety signals among patients who continued denosumab or among patients who switched from zoledronic acid to denosumab. Osteonecrosis of the jaw rates increased with increasing exposure to denosumab, while hypocalcemia rates were similar between the blinded treatment and open-label extension phases.
No new safety signals were identified for long-term denosumab therapy in patients with metastatic breast or prostate cancer and bone metastases.
Sign Up for Free e-newsletters
- Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
- Is Radioimmunotherapy a Path Forward for Melanoma?
- Handling Chemotherapy Premedications
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|